Jared Gollob Kymera Therapeutics, Inc. (KYMR) insider trading activity

Jared Gollob is Chief Medical Officer of Kymera Therapeutics, Inc.. Currently has a direct ownership of 95,470 shares of KYMR, which is worth approximately $4.21 Million. The most recent transaction as insider was on Jul 16, 2024, when has been sold 23,145 shares (Common Stock) at a price of $45.84 per share, resulting in proceeds of $1,060,966. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 95.5K

0% 3M change

27.79% 12M change

Total Value Held $4.21 Million

Jared Gollob Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 16 2024	SELL Open market or private sale	$1,060,966 $45.84 p/Share	23,145 Reduced 19.51%	95,470 Common Stock
Jul 16 2024	BUY Exercise of conversion of derivative security	$48,141 $2.08 p/Share	23,145 Added 16.3%	118,885 Common Stock
Jul 15 2024	SELL Open market or private sale	$742,943 $45.15 p/Share	16,455 Reduced 14.67%	95,740 Common Stock
Jul 15 2024	BUY Exercise of conversion of derivative security	$34,226 $2.08 p/Share	16,455 Added 12.79%	112,195 Common Stock
Mar 04 2024	SELL Open market or private sale	$141,618 $42.35 p/Share	3,344 Reduced 3.37%	95,740 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	24,375 Added 19.74%	99,084 Common Stock
Feb 27 2024	SELL Open market or private sale	$18,000 $45.0 p/Share	400 Reduced 0.53%	74,709 Common Stock
Feb 27 2024	BUY Exercise of conversion of derivative security	$832 $2.08 p/Share	400 Added 0.53%	75,109 Common Stock
Feb 09 2024	SELL Open market or private sale	$1,648,936 $35.74 p/Share	46,137 Reduced 38.18%	74,709 Common Stock
Feb 09 2024	BUY Exercise of conversion of derivative security	$95,964 $2.08 p/Share	46,137 Added 27.63%	120,846 Common Stock
Mar 02 2023	SELL Open market or private sale	$40,419 $31.14 p/Share	1,298 Reduced 1.71%	74,709 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	18,750 Added 19.79%	76,007 Common Stock
May 04 2022	BUY Exercise of conversion of derivative security	$34,000 $1.7 p/Share	20,000 Added 25.89%	57,257 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	12,600 Added 25.27%	37,257 Common Stock
Nov 02 2021	SELL Open market or private sale	$953,446 $63.58 p/Share	14,996 Reduced 37.82%	24,657 Common Stock
Nov 02 2021	BUY Exercise of conversion of derivative security	$31,192 $2.08 p/Share	14,996 Added 27.44%	39,653 Common Stock
Nov 01 2021	SELL Open market or private sale	$2,628,439 $61.85 p/Share	42,497 Reduced 63.28%	24,657 Common Stock
Nov 01 2021	BUY Exercise of conversion of derivative security	$41,832 $1.7 p/Share	24,607 Added 26.82%	67,154 Common Stock
Mar 15 2021	SELL Open market or private sale	$620,052 $60.17 p/Share	10,305 Reduced 19.5%	42,547 Common Stock
Mar 15 2021	BUY Exercise of conversion of derivative security	$10,218 $1.31 p/Share	7,800 Added 12.86%	52,852 Common Stock
Mar 11 2021	SELL Open market or private sale	$281,935 $60.05 p/Share	4,695 Reduced 9.44%	45,052 Common Stock
Mar 11 2021	BUY Exercise of conversion of derivative security	$2,882 $1.31 p/Share	2,200 Added 4.24%	49,747 Common Stock
Feb 24 2021	SELL Open market or private sale	$441,644 $50.91 p/Share	8,675 Reduced 15.43%	47,547 Common Stock
Feb 23 2021	SELL Open market or private sale	$957,500 $49.65 p/Share	19,285 Reduced 25.54%	56,222 Common Stock
Feb 22 2021	SELL Open market or private sale	$479,144 $52.63 p/Share	9,104 Reduced 10.76%	75,507 Common Stock

Jared Gollob

Chief Medical Officer

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KYMR shares.

Notify only if

Value

Insider Trading

Get notified when an Kymera Therapeutics, Inc. insider buys or sells KYMR shares.

Notify only if

Operation

Value

Type

News

Receive news related to Kymera Therapeutics, Inc.

Track Activities on KYMR

Account